Spotlight Center on HIV Prevention Today

Glaxo Drug Discovery and Development Research Grants (Including Microbicides); Deadline July 31

May 30, 2003

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

GlaxoSmithKline will award research grants from $25,000 to $150,000 ($500,000 total) "for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic." These grants "are intended to further the development of inventive treatments for HIV/AIDS, including: therapies aimed at treating infection; prophylactic vaccines; or microbicides designed to prevent transmission of the virus." Applications will be judged by a panel of outside experts; recipients will be announced at the ICAAC conference in September 2003; and the grants will be paid by November 1. There is no obligation to license resulting technologies to Glaxo.

For more information and application forms, visit or call 888-527-6935.

ISSN # 1052-4207

Copyright 2003 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.


Back to the AIDS Treatment News May 30, 2003 contents page.

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.